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Abstract 
We investigated the predictive value of the 3-month BCR-ABL1 transcript levels in terms of 
responses and outcome of 44 children and adolescents (<18 years at diagnosis) with 
chronic myeloid leukemia (CML) treated with high-dose imatinib (IM) (340 mg/m2/day). The 
transcript cutoff levels of 1% and 10% BCR-ABL1 IS were not predictive of either complete 
cytogenetic response at any time, overall molecular response (MR) and complete MR 
(CMR), and progression-free survival probabilities at 5 years. The 3-month transcript levels 
in children and adolescents with CML treated with high-dose IM do not appear to be 
informative for the prediction of outcomes. 
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Introduction 
The achievement of early and/or deep response has been demonstrated to predict a 
significantly better outcome in adults with chronic myeloid leukemia (CML) in chronic 
phase (CP) treated with either imatinib (IM) or second-generation tyrosine kinase inhibitors 
(TKIs) (Branford et al, 2012; Hanfstein B et al, 2012; Marin et al, 2012; Jain et al, 2013; 
Jabbour et al, 2014). Consistent with this, the latest European LeukemiaNet (ELN) 
recommendations have updated the optimal response criteria to first-line treatment with 
any TKI, defining a BCR-ABL1 transcript levels >10% and/or >1% and/or >0.1% at 3, 6 
and 12 months, respectively, as a warning (Baccarani et al, 2013). Recently, early 
molecular response (EMR), defined by a BCR-ABL1 transcript level ≤10%, at 3 months 
has also been reported to predict a better outcome in 40 CP-CML children treated with IM 
at a standard dose (260 mg/m2/day) (Millot et al, 2014). The aim of the present study was 
to analyze the predictive value of the BCR-ABL1 transcript levels at 3 months in terms of 
cytogenetic and molecular responses, and the outcome in a cohort of children and 
adolescents with CP-CML treated with high-dose IM. 
Patients and Methods 
Between March 2001 and March 2014, 53 patients younger than 18 years of age with 
newly diagnosis of CML in CP were treated in 11 Italian pediatric centers according to the 
local guidelines (Giona et al, 2015). Treatment response of 39 of them have been recently 
reported (Giona et al, 2015). The scheduled daily dosage of IM was 340 mg/m2/daily. 
Evaluations of bone marrow (BM) morphology and cytogenetics were planned before and 
during IM therapy every 3 months. Quantitative reverse transcription polymerase chain 
reaction (qPCR) on peripheral blood (PB) monthly and on BM every 3 months was 
scheduled for molecular monitoring. BCR-ABL1 transcript levels were measured in a 
central laboratory according to a standardized method (Beillard et al, 2003; Gabert et al, 
2003). Results were converted to the International Scale (IS) (White et al, 2010). Patients 
with available BCR-ABL1 transcript levels at 3 months and a minimum follow-up of 12 
months were considered for landmark analyses. Hematologic and cytogenetic response 
(CyR) criteria were defined according to the ELN recommendations (Baccarani et al 2006, 
2009). Major molecular response (MMR) was defined as ≤0.1% BCR-ABL1 IS, while 
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molecular response (MR) was considered as ≤0.01% BCR-ABL1 IS. Complete molecular 
response (CMR) was used to indicate levels of disease ≤0.0032% BCR-ABL1 IS or 
undetectable. Transcript levels ≤10% and ≤1% BCR-ABL1 IS at 3 months after starting IM 
were defined as EMR and deep EMR, respectively. BCR-ABL1 transcript levels (≤10% vs 
>10%, and ≤1% vs >1%) at 3 months were used to perform landmark analyses to assess 
the association between EMR and both the response rates and outcome. Cumulative 
incidence of responses and progression-free survival (PFS), defined as survival without 
loss of either CyR or MR or evolution to blastic crisis, were estimated using the Kaplan-
Meier method. Comparisons between groups were performed using the Chi-square or the 
Fisher’s exact test and the Wilcoxon test, as appropriate. All statistical comparisons were 
based on two-tailed tests with a nominal significance level of 5%.  
This study, named CML-Petit-01, was approved by the Institutional Ethic Committee for 
each participating institution. 
 
Results and Discussion 
Eight of the 53 patients had a missing BCR-ABL1 qPCR assessment 3 months after 
starting treatment and 1 patient stopped IM because of severe side effects. Accordingly, 
44 CP-CML patients (females: 17, males: 27) with a median age at diagnosis of 11.2 years 
(range: 3.1-15,8) were evaluated. Overall, 92.5%, 85%, 56% and 39% of patients achieved 
complete CyR (CCyR), MMR, MR and CMR after a median time of 6.2 (range 3.5-8.6), 
13.4 (range 9.4-19.7), 14.9 (range 10.1-24.1) and 15 (range 10.1-24.8) months, 
respectively. Three months after the start of IM, BCR-ABL1 transcript levels >10% IS were 
detected in 9/44 (20.5%) patients, whereas 18/44 (41%) and 17/44 (38.5%) patients had 
BCR-ABL1 IS of >1% to ≤10% and ≤1%, respectively. To assess the association between 
EMR and disease outcome, we took into account two 3-month transcript cutoff levels, 1% 
and 10% BCR-ABL1 IS. When children were classified according to the transcript level at 
3 months using the 10% IS cutoff, those with EMR had significantly higher response rates 
after 6 months of treatment compared to those with BCR-ABL1 IS >10%: 95% vs 55.5%, 
P=.031 and 78% vs 22%, P=.003 for CCyR and BCR-ABL1 IS ≤10%, respectively (Table 
I). Likewise, EMR was significantly predictive of overall MMR rate (94% of patients with 
BCR-ABL1 IS ≤10% vs 62.5% of those with higher transcript values, P=.041), but no for 
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overall CCyR, MR and CMR rates (Table I). When patients were classified according to 
the transcript level at 3 months using the 1% IS cutoff, children with BCR-ABL1 IS ≤1% 
had higher molecular response rates after 6 (100% vs 46%, P=.001), 9 (100% vs 65%, 
P=.041) and 12 months (91% vs 50%, P=.021) compared to those with values greater than 
1%; nonetheless, an EMR was not predictive of CCyR at any time and overall MMR, MR 
and CMR (Table I). The clinical and hematological features at diagnosis, as well as the 
dose of IM administered during the first 3 months of treatment, were similar in patients who 
achieved an EMR and in those with higher transcript levels (Table IS). Treatment was 
successfully discontinued in 3 patients with sustained and prolonged CMR; interestingly, 
all of them have achieved a deep EMR after 3 months of IM. In addition, 7 patients (all but 
1 with BCR-ABL1 IS ≤10% after 3 months of treatment) stopped IM to undergo allogeneic 
hematopoietic stem cell transplantation; whereas 13 children had to discontinue treatment 
because of toxicity (n= 3) or disease progression (n= 10). Although about one third of 
patients had to interrupt IM due to a failure, none of our patients died. With a median 
follow-up of 73.5 months (range, 15-151.3), the overall PFS probability at 10 years was 
57.7% (95% CI, 38.4-86.8). The estimated 5-year PFS probability comparing patients with 
BCR-ABL1 values ≤10% vs those with values >10% resulted 85.9% vs 76.2%, P = .4671 
(Figure 1A). Likewise, no statistically significant differences in both 5-year and 10-year 
PFS probabilities were observed between patients with deep EMR and those with >1% 
BCR-ABL1 IS, (92.3% vs 78.3% and 60.6% vs 67.1%, P =.3463) (Figure 1B).  
Marin et al were the first to report that BCR-ABL1 transcript levels >10% IS after 3 months 
of treatment are associated with impaired PFS and overall survival in CP-CML patients 
treated with standard doses of IM (400 mg/daily) (Marin et al, 2012). Afterwards, the 
predictive value of an early molecular response in outcomes of adult CP-CML patients 
treated with frontline IM or second-generation TKIs has been confirmed by several studies 
(Branford et al, 2012; Hanfstein  et al, 2012; Jain et al, 2013; Deininger et al, 2014; 
Hughes et al, 2014; Jabbour et al, 2014). Some of these reports showed that adults 
starting IM frontline at higher doses (600-800 mg/daily) had a higher probability of 
achieving an EMR compared to patients treated with the standard dose of IM (Deininger et 
al, 2014; Hughes et al, 2014). Recently, Millot et al. reported that children with BCR-ABL1 
≤10% 3 months after treatment with standard doses of IM (260 mg/m2 equated to 400 mg 
daily in adults) had higher rates of response at 12 months and a better PFS compared with 
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those with greater transcript values (Millot et al, 2014). Our study including a cohort of 
children similar to that reported by Millot et al (2014) provide intriguing information. First at 
all, the proportions of patients who achieved BCR-ABL1 transcript levels ≤10% (79.5%) 
and ≤1% (38.6%) after 3 months of treatment were similar to those observed in adults 
treated with high-dose IM (600-800 mg/daily) (Hanfstein et al, 2012; Jain et al, 2013; 
Deininger et al, 2014) and higher than those reported  by Millot et al (2014). Accordingly, 
the low proportion of children who failed to achieve an EMR after 3 months and the high 
overall cytogenetic and molecular response rates obtained in our cohort of patients treated 
with high doses of IM suggest that IM exposure is an important factor influencing 
responses and outcomes. Moreover, in our experience the BCR-ABL1 IS values at 3 
months are not predictive of overall MMR, MR and CMR rates, and outcomes. Indeed, the 
PFS probabilities were not influenced by an EMR at 3 months, as reported both in adults 
treated with high-dose IM (Hanfstein et al, 2012; Jain et al, 2013; Deininger et al, 2014) 
and in children receiving standard doses of IM (Millot et al, 2014).   
In conclusion, our study shows that the 3-month transcript cut-off levels of 1% and 10% 
BCR-ABL1 IS in children and adolescents with CML treated with high doses of IM do not 
appear to be informative for the prediction of outcome. Cooperative studies including 
larger numbers of patients are required to provide definitive thresholds of the transcript 
levels and timing on which to base therapeutic decisions for children and adolescents with 
CML treated with IM. 
 
 
 
 
 
 
 
 
 
7 
 
 
Acknowledgments 
The authors gratefully acknowledge Alfonso Piciocchi (GIMEMA Data Center) and Roberto 
Latagliata for the statistical data help. 
 
Author contributions 
Contribution: F.G. contributed to the study design, enrolled patients, recorded data and 
wrote the manuscript; G.S. coordinated molecular analyses and reviewed the manuscript; 
M.S. analyzed data; G.M., G.I., M.C.P., C.M., N.S., S.L., R. M, R.B., C.C., C.C., M.L.M., 
F.T. enrolled patients and recorded data; M.N. and AL performed cytogenetic analyses; 
D.D. performed molecular analysis; A.B. and F.L. review the manuscript; R.F. overviewed 
the study and reviewed the manuscript.  
 
Competing  interests 
GS was a consultant for Bristol-Meyers-Squibb, Novartis, Ariad and Pfizer. All other 
authors declare no competing financial interests. 
 
Supporting informations 
Additional Supporting Information may be found in the online version of this article: 
Table IS. Patient features according to the BCR-ABL1 transcript levels 3 months after 
starting imatinib 
 
 
8 
 
References 
Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B., Appelbaum, F., 
Apperley, J., Cervantes, F., Cortes, J., Deininger, M., Gratwohl, A., Guilhot, F., 
Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Niederwieser, D., Silver, R., 
Hehlmann, R. & European LeukemiaNet (2006) Evolving concepts in the management 
of chronic myeloid leukemia: recommendations from an expert panel on behalf of the 
European LeukemiaNet. Blood, 108, 1809-1820.  
Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J.,  Cervantes, 
F., Deininger, M., Gratwohl, A., Guilhot, F., Hochhaus, A., Horowitz, M., Hughes, T., 
Kantarjian, H., Larson,.R., Radich, J., Simonsson, B., Silver, R.T., Goldman, J., 
Hehlmann, R. & European LeukemiaNet (2009) Chronic myeloid leukemia: an update of 
concepts and management recommendations of European LeukemiaNet. Journal of 
Clinical Oncology,  27, 6041-6051.  
Baccarani, M., Deininger, M.W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J.F.,  
Cervantes, F., Clark, R.E., Cortes, J.E., Guilhot, F., Hjorth-Hansen, H., Hughes, T.P., 
Kantarjian, H.M., Kim, D.W., Larson, R.A., Lipton, J.H., Mahon, F.X., Martinelli, G., 
Mayer, J., Müller, M.C., Niederwieser, D., Pane, F., Radich, J.P., Rousselot, P., Saglio, 
G., Saußele, S., Schiffer, C., Silver, R., Simonsson, B., Steegmann, J.L., Goldman, J.M. 
& Hehlmann, R. (2013) European LeukemiaNet recommendations for the management 
of chronic myeloid leukemia: 2013. Blood 2013, 122, 872-884.  
Branford, S., Kim, D.W., Soverini, S., Haque, A., Shou, Y., Woodman, R.C., Kantarjian, 
H,M,, Martinelli, G., Radich, J.P., Saglio, G., Hochhaus, A., Hughes, T.P., Müller, M.C. 
(2012) Initial molecular response at 3 months may predict both response and event-free 
survival at 24 months in imatinib-resistant or intolerant patients with Philadelphia 
chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. 
Journal of Clinical Oncology, 30, 4323-4329. 
Deininger, M.W., Kopecky, K.J., Radich, J.P., Kamel-Reid, S., Stock, W., Paietta, E., 
Emanuel, P.D., Tallman, M., Wadleigh, M., Larson, R.A., Lipton, J.H., Slovak, M.L., 
Appelbaum, F.R., Druker, B.J. (2014) Imatinib 800 mg daily induces deeper molecular 
responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup 
randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid 
leukaemia. British Journal of Haematology, 164, 223-232. 
9 
 
Gabert, J., Beillard, E., van der Velden V.H., Bi, W., Grimwade, D., Pallisgaard, N., 
Barbany, G., Cazzaniga, G., Cayuela, J.M., Cavé, H., Pane, F., Aerts, J.L., De Micheli, 
D., Thirion, X., Pradel, V., González, M., Viehmann, S., Malec, M., Saglio, G., van 
Dongen, J.J. (2003) Evaluation of candidate control genes for diagnosis and residual 
disease detection in leukemic patients using 'real-time' quantitative reverse-
transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. 
Leukemia, 17, 2474-2486. 
Gabert, J., Beillard, E., van der Velden V.H., Bi, W., Grimwade, D., Pallisgaard, N., 
Barbany, G., Cazzaniga, G., Cayuela, J.M., Cavé, H., Pane, F., Aerts, J.L., De Micheli, 
D., Thirion, X., Pradel, V., González, M., Viehmann, S., Malec, M., Saglio, G., van 
Dongen, J.J. (2003) Standardization and quality control studies of 'real-time' quantitative 
reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual 
disease detection in leukemia - a Europe Against Cancer program. Leukemia, 17, 2318-
2357.  
Giona, F., Putti, M.C., Micalizzi, C., Menna, G., Moleti, M.L, Santoro, N., Iaria, G., 
Ladogana, S., Burnelli, R., Consarino, C., Varotto, S., Tucci, F., Messina, C., Nanni, M., 
Diverio, D., Biondi, A., Pession, A., Locatelli, F., Piciocchi, A., Gottardi, E., Saglio, G., 
Foà, R. (2015) Long-term results of high-dose imatinib in children and adolescents with 
chronic myeloid leukaemia in chronic phase: the Italian experience. British Journal of 
Haematology, 170, 398-407. 
Hanfstein, B., Müller, M.C., Hehlmann, R., Erben, P., Lauseker, M., Fabarius, A.,  
Schnittger, S., Haferlach, C., Göhring, G., Proetel, U., Kolb, H.J., Krause, S.W., 
Hofmann, W.K., Schubert, J., Einsele, H., Dengler, J., Hänel, M., Falge, C., Kanz, L., 
Neubauer, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C.F., Branford, S., 
Hughes, T.P., Spiekermann, K., Baerlocher, G.M., Pfirrmann, M., Hasford, J., Saußele, 
S., Hochhaus, A.; SAKK & German CML Study Group (2012) Early molecular and 
cytogenetic response is predictive for long-term progression-free and overall survival in 
chronic myeloid leukemia (CML). Leukemia, 26, 2096-2102.  
Hughes, T.P., Saglio, G., Kantarjian, H.M., Guilhot, F., Niederwieser, D., Rosti, G., 
Nakaseko, C., De Souza, C.A., Kalaycio, M.E., Meier, S., Fan, X., Menssen, H.D., 
Larson, R.A., Hochhaus, A. (2014) Early molecular response predicts outcomes in 
patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or 
imatinib. Blood, 123,1353-1360. 
10 
 
Jabbour, E., Kantarjian, H.M., Saglio, G., Steegmann, J.L., Shah, N.P., Boqué, C.,  Chuah, 
C., Pavlovsky, C., Mayer, J., Cortes, J., Baccarani, M., Kim, D.W., Bradley-Garelik, 
M.B., Mohamed, H., Wildgust, M. & Hochhaus, A. (2014) Early response with dasatinib 
or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 
trial (DASISION). Blood, 123, 494-500. 
Jain, P., Kantarjian, H., Nazha, A., O'Brien, S., Jabbour, E., Romo, C.G., Pierce, S., 
Cardenas-Turanzas, M., Verstovsek, S., Borthakur, G., Ravandi, F., Quintás-Cardama, 
A., Cortes, J. (2013) Early responses predict better outcomes in patients with newly 
diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor 
modalities. Blood, 121, 4867-4874.  
Marin, D., Ibrahim, A.R., Lucas, C., Gerrard, G., Wang, L., Szydlo, R.M., Clark, R.E., 
Apperley, J.F., Milojkovic, D., Bua, M., Pavlu, J., Paliompeis, C., Reid, A., Rezvani, K., 
Goldman, J.M. & Foroni, L. (2012) Assessment of BCR-ABL1 transcript levels at 3 
months is the only requirement for predicting outcome for patients with chronic myeloid 
leukemia treated with tyrosine kinase inhibitors. Journal of  Clinical Oncology, 30, 232-
238. 
Millot, F., Guilhot, J., Baruchel, A., Petit, A., Bertrand, Y., Mazingue, F., Lutz, P.,  Vérité, 
C., Berthou, C., Galambrun, C., Sirvent, N., Yakouben, K., Schmitt, C., Gandemer, V., 
Reguerre, Y., Couillault, G., Mechinaud, F. & Cayuela, J.M. (2014) Impact of early 
molecular response in children with chronic myeloid leukemia treated in the French 
Glivec phase 4 study. Blood, 124, 2408-2410. 
White, H.E., Matejtschuk, P., Rigsby, P., Gabert, J., Lin, F., Lynn Wang, Y., Branford, S., 
Müller, M.C., Beaufils, N., Beillard, E., Colomer, D., Dvorakova, D., Ehrencrona, H., 
Goh, H.G,, El Housni, H., Jones, D., Kairisto, V., Kamel-Reid, S., Kim, D.W., 
Langabeer, S., Ma, E.S., Press, R.D., Romeo, G., Wang, L., Zoi, K., Hughes, T., Saglio, 
G., Hochhaus, A., Goldman, J.M., Metcalfe, P., Cross, NC. (2010) Establishment of the 
first World Health Organization International Genetic Reference Panel for quantitation of 
BCR-ABL mRNA. Blood, 116, e111-117.  
   
 
 
 
11 
 
      Table I. Rates of cytogenetic and molecular responses according to the BCR-ABL1 transcript levels at 3 month. 
             
 BCR-ABL IS at 3 mo 
        < 10%                          >10% P 
BCR-ABL IS at 3 mo 
 < 1%                                  >1%  P 
N^ of pts (%) 35 (79.5%) 9 (20.5%) 
 
17 (38.6%) 27 61.4%) 
 
CCyR 
  At 6 mo, n(%) 
  Overall, n(%)  
 
18/19  (95%) 
29/31 (93.5%) 
 
5/9  (55.5%) 
8/9 (89%) 
.003 
.64 
10/17 (59%)  
15/15 (100%) 
13/27 (48%) 
24/25 (96%) 
.678 
.433 
BCR-ABL1 IS  <1% 
  At 6 mo, n (%)                                                   
  At 9 mo, n (%) 
 
21/27 (78%)
20/23 (87%) 
 
2/9 (22%) 
4/9 (44.5%) 
 
.003 
.013 
 
12/12 (100%) 
9/9 (100%) 
 
11/24 (46%) 
15/23 (65%) 
 
.001 
.041 
MMR 
  At  12 mo, n (%)    
  At  18 mo, n(%) 
  Overall, n (%)               
 
18/25 (72%) 
17/20 (85%) 
30/33 (91%) 
 
3/8 (37.5%) 
3/7 (43%) 
5/8 (62.5%) 
 
.077 
.029 
.041 
 
10/11 (91%) 
10/10 (100%) 
16/17 (94%) 
 
11/22 (50%) 
10/17 (59%) 
18/23 (78%) 
 
.021 
.063 
.165 
MR 
  At  24 mo, n (%) 
  Overall, n (%)                     
 
12/19 (63%) 
20/33 (61%) 
 
1/4 (25%) 
3/8 (37.5%) 
 
.125 
.237 
 
4/9 (44.5%) 
11/17 (64.7%) 
 
11/13 (84.5%) 
12/23 (52%) 
 
.731 
.428 
CMR 
  Overall,  n (%) 
 
15/33 (45.5%) 
 
1/8 (12.5%) 
 
.064 
 
8/17 (47%) 
 
9/23 (39%) 
 
.616 
CCyR = complete cytogenetic response; MMR = major molecular response; MR = molecular response;                                                    
CMR = complete molecular response. 
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Figure legend  
 
Figure 1. Progression-free survival (PFS) probability according to the BCR-ABL1 
transcript level cut-off  at 3 month: 10% IS (A) and 1% IS (B). The number of patients at 
risk per period are shown. Patients lost to follow-up were censored.  
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